Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.44 |
| ▸ | GRB2 | P62993 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16338735 | 1.00 | OPRM1 (0.47) | OPRM1OPRK1CAPN1GRB2APLNR | |
| SCHEMBL17210470 | 0.97 | OPRM1 (0.49) | OPRM1OPRK1APLNRCXCR4 | |
| SCHEMBL12261069 | 0.94 | GRB2 (0.50) | OPRM1OPRK1CAPN1GRB2CXCR4 | |
| SCHEMBL14227389 | 0.94 | GRB2 (0.50) | OPRM1OPRK1CAPN1GRB2CXCR4 | |
| SCHEMBL12899266 | 0.94 | GRB2 (0.50) | OPRM1OPRK1CAPN1GRB2CXCR4 | |
| SCHEMBL13084631 | 0.94 | GRB2 (0.50) | OPRM1OPRK1CAPN1GRB2CXCR4 | |
| SCHEMBL12237919 | 0.94 | GRB2 (0.50) | OPRM1OPRK1CAPN1GRB2CXCR4 | |
| SCHEMBL12899371 | 0.93 | OPRM1 (0.44) | OPRM1OPRK1CAPN1GRB2APLNR | |
| SCHEMBL12314900 | 0.93 | OPRM1 (0.44) | OPRM1OPRK1CAPN1GRB2APLNR | |
| SCHEMBL1247799 | 0.91 | OPRM1 (0.48) | OPRM1OPRK1GRB2CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110262366-A1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE | BRACCO INTERNATIONAL B.V. (NL) | 2011-10-27 | — | — | US | disclosed |
| US-20110262366-A1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE | BRACCO INTERNATIONAL B.V. (NL) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262366-A1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE | VCAM1, FLT1, EDNRA | OPRM1 1803/4885OPRK1 1592/4885CAPN1 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.